Business
Notice of Results and Notice of AGM
Notice of Results and Notice of AGM.
About this update from Bioventix Plc
[{"type":"text","content":"\n \nBioventix plc\n\n(“Bioventix†or “the Companyâ€)\n\nNotice of Results and Notice of AGM \n\nBioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2018 on 8 October 2018.\n\nThe Company’s Annual General Meeting will be held on Thursday 6 December at 2.00p.m at Farnham Castle, Castle Street, Farnham, Surrey, GU9 0AG. \n\nFor further information please contact:\n\n\n\nBioventix plcPeter Harrison\nChief Executive Officer\nTel: 01252 728 001\n\n\n\n\n\n\n\n\n\nfinnCap LtdGeoff Nash/Simon HicksAlice Lane\nCorporate FinanceECM\nTel: 020 7220 0500\n\n\n\nAbout Bioventix plc:\n\nBioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.\n\n ","length":2525,"tagName":"div"}]